DDInter605 DDInter1397
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) palliates {v} (Disease) endogenous depression
endogenous depression {u} (Disease) is palliated by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desvenlafaxine
Desvenlafaxine {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Duloxetine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) downregulates {v} (Gene) COTL1
COTL1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Tirofiban {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Meclofenamic acid
Meclofenamic acid {u} (Compound) downregulates {v} (Gene) CSRP1
CSRP1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paroxetine (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) palliates endogenous depression (Disease) and endogenous depression (Disease) is palliated by Paroxetine (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Paroxetine (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Paroxetine (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine (Compound) downregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Paroxetine (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Paroxetine (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Paroxetine (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Paroxetine (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Paroxetine (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Meclofenamic acid and Meclofenamic acid (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is downregulated by Paroxetine (Compound)